Regulatory Submission Blog

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

Latest updates on SEND v4.0

Marc Ellison

With the new Implementation Guide due to go on public review this coming August, we take a closer look at the scope of SEND 4.0.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

SEND @SOT 2023: Same, but different

Marc Ellison

A look at the main SEND discussion points at SOT 2023

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

Is there really that much to say about SEND?

Marc Ellison

When it comes to SEND “What is there to talk about?”, actually quite a lot.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

Who uses the CoDEx document anyway?

Marc Ellison

The Confirmed Data Endpoints for Exchange (CoDEx) is CDISC’s method of addressing the scope for SEND, down to the individual endpoints.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

Are you ready for a tighter standard?

Marc Ellison

As work continues on the content and updates for SEND 4.0, there’s a definite change in approach in an effort to make study representation more uniform, and to give implementors much clearer direction.

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.